Takeda Announced That The U.S. Food And Drug Administration (Fda) Has Accepted Biologics Licence Application (Bla) For Tak-755, An Enzyme Replacement Therapy For The Treatment Of Congenital Thrombotic Thrombocytopenic Purpura (Cttp), An Adamts13 Deficiency Disorder.Tak-755 Is The First And Only Recombinant Adamts13 Protein In Development. It Provides Targeted Therapy To Address An Unmet Medical Need In Patients With Thrombotic Thrombocytopenic Purpura (Ttp), By Replacing The Missing Or Deficient Adamts13 EnzymeThere Is A Critical Need For Treatment Options For People Living With Cttp, An Ultra-Rare, Life-Threatening Disorder That Has No Therapies Specifically Approved For Prophylactic Treatment. If Approved, Tak-755 Will Be The First And Only Recombinant Adamts13 (Radamts13) Replacement Therapy For Cttp, A Disorder With Considerable Unmet Patient Need.Cttp Is An Ultra-Rare Inherited Form Of Thrombotic Thrombocytopenic Purpura (Ttp), A Chronic And Debilitating Clotting Disorder Caused By A Deficiency In Adamts13 Protease. Acute Ttp Has A Mortality Rate Of >90 Percent, If Left Untreated.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!